Case Report: Neurological Adverse Events in Subject With Myasthenia Gravis After PCSK9 Inhibitor Administration
Source : https://pubmed.ncbi.nlm.nih.gov/38532873/
Based on the neurologist's conclusion, it can be assumed that in this case, treatment with PCSK9i resulted in significant worsening of the patient's chronic disease.
In this case, treatment with a PCSK9 inhibitor resulted in significant worsening of the patient's chronic disease.
Anti-Titin Antibodies in a Cohort of Myasthenia Gravis Patients
Source : https://pubmed.ncbi.nlm.nih.gov/38505076/
The presence of anti-titin antibodies appears to correlate with underlying thymoma in early-onset MG cases and with generalized MG in late-onset cases. Prospective studies are needed to further study this...
Anti-titin positivity correlated with thymoma in patients with age of onset <50 years, and it was significantly associated with gMG in the late-onset group.
The rate of sustained improvement in the Myasthenia Gravis Activities of Daily Living score was significantly higher in the batoclimab group than in the placebo group.
How Should Newer Therapeutic Agents Be Incorporated Into the Treatment of Patients With Myasthenia Gravis?
Source : https://pubmed.ncbi.nlm.nih.gov/38308492/
Generalized myasthenia gravis (gMG) is a postsynaptic neuromuscular junction disorder that results in fatigable muscle weakness. The traditional treatment approach includes the use of acetylcholinesterase inhibitors, corticosteroids, and steroid-sparing immunosuppressant...
As additional drugs enter the marketplace with unique mechanisms of action, routes of administration, and dosing schedules, the placement of the novel therapeutic agents in the generalized myasthenia gravis treatment algorithm will likely evolve.
Clinicopathological Predictors of Postoperative Long-Term Myasthenic Status in Resected Thymoma With Myasthenia Gravis
Source : https://pubmed.ncbi.nlm.nih.gov/38416144/
The WHO type of thymoma is an informative predictor of postoperative MG status in patients with MG-related thymoma.
WHO type (A-AB or B1-B3) was an independent predictor of worsening episodes of myasthenia gravis based on the quantitative myasthenia gravis score (type B1-B3).